471 related articles for article (PubMed ID: 26995002)
1. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.
Walle JV; Delmas Y; Ardissino G; Wang J; Kincaid JF; Haller H
J Nephrol; 2017 Feb; 30(1):127-134. PubMed ID: 26995002
[TBL] [Abstract][Full Text] [Related]
2. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.
Licht C; Greenbaum LA; Muus P; Babu S; Bedrosian CL; Cohen DJ; Delmas Y; Douglas K; Furman RR; Gaber OA; Goodship T; Herthelius M; Hourmant M; Legendre CM; Remuzzi G; Sheerin N; Trivelli A; Loirat C
Kidney Int; 2015 May; 87(5):1061-73. PubMed ID: 25651368
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
Menne J; Delmas Y; Fakhouri F; Licht C; Lommelé Å; Minetti EE; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
BMC Nephrol; 2019 Apr; 20(1):125. PubMed ID: 30971227
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
[TBL] [Abstract][Full Text] [Related]
7. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
[TBL] [Abstract][Full Text] [Related]
8. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
[TBL] [Abstract][Full Text] [Related]
9. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
[TBL] [Abstract][Full Text] [Related]
11. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
Kant S; Bhalla A; Alasfar S; Alachkar N
BMC Nephrol; 2020 May; 21(1):189. PubMed ID: 32434487
[TBL] [Abstract][Full Text] [Related]
12. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
[TBL] [Abstract][Full Text] [Related]
13. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
Cugno M; Gualtierotti R; Possenti I; Testa S; Tel F; Griffini S; Grovetti E; Tedeschi S; Salardi S; Cresseri D; Messa P; Ardissino G
J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
Gediz F; Payzin BK; Ecemis S; Güler N; Yilmaz AF; Topcugil F; Berdeli A
Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
Fakhouri F; Fila M; Provôt F; Delmas Y; Barbet C; Châtelet V; Rafat C; Cailliez M; Hogan J; Servais A; Karras A; Makdassi R; Louillet F; Coindre JP; Rondeau E; Loirat C; Frémeaux-Bacchi V
Clin J Am Soc Nephrol; 2017 Jan; 12(1):50-59. PubMed ID: 27799617
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
Fakhouri F; Fila M; Hummel A; Ribes D; Sellier-Leclerc AL; Ville S; Pouteil-Noble C; Coindre JP; Le Quintrec M; Rondeau E; Boyer O; Provôt F; Djeddi D; Hanf W; Delmas Y; Louillet F; Lahoche A; Favre G; Châtelet V; Launay EA; Presne C; Zaloszyc A; Caillard S; Bally S; Raimbourg Q; Tricot L; Mousson C; Le Thuaut A; Loirat C; Frémeaux-Bacchi V
Blood; 2021 May; 137(18):2438-2449. PubMed ID: 33270832
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis.
Gäckler A; Schönermarck U; Dobronravov V; La Manna G; Denker A; Liu P; Vinogradova M; Yoon SS; Praga M
BMC Nephrol; 2021 Jan; 22(1):5. PubMed ID: 33407224
[TBL] [Abstract][Full Text] [Related]
18. Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan.
Ito S; Hataya H; Ashida A; Hamada R; Ishikawa T; Ishikawa Y; Shimono A; Konomoto T; Miyazawa T; Ogura M; Tanaka K; Kagami S
Nephrol Dial Transplant; 2023 Feb; 38(2):414-424. PubMed ID: 35438790
[TBL] [Abstract][Full Text] [Related]
19. [Use of Eculizumab in atypical hemolytic uremic syndrome after renal transplantation].
Teixeira CI; Mota RG; Afonso BG; Carneiro TV; Meira GS; Mendonça DU
J Bras Nefrol; 2015; 37(1):127-30. PubMed ID: 25923760
[TBL] [Abstract][Full Text] [Related]
20. First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients.
Yüksel S; Evrengül H; Özçakar ZB; Becerir T; Yalçın N; Korkmaz E; Ozaltin F
Paediatr Drugs; 2016 Dec; 18(6):413-420. PubMed ID: 27646857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
